| Treatment . | The response rate to first-line therapy, n/N (%) . | The response rate to second-line therapy, n/N (%) . | ||
|---|---|---|---|---|
| ORR . | CRR . | ORR . | CRR . | |
| Immunosuppressor-based therapy | 20/23 (87.0%) | 11/23 (47.8%) | 6/9 (66.7%) | 2/9 (22.2%) |
| MTX-based | 12/14 (85.7%) | 7/14 (50.0%) | 0/2 (0.0%) | 0/2 (0.0%) |
| CsA-based | 7/8 (87.5%) | 3/8 (37.5%) | 5/5 (100.0%) | 2/5 (40.0%) |
| CTX-based | 1/1 (100.0%) | 1/1 (100.0%) | 1/1 (100.0%) | 0/1 (0.0%) |
| Other therapies | 3/4 (75.0%) | 3/4 (75.0%) | ||
| Treatment . | The response rate to first-line therapy, n/N (%) . | The response rate to second-line therapy, n/N (%) . | ||
|---|---|---|---|---|
| ORR . | CRR . | ORR . | CRR . | |
| Immunosuppressor-based therapy | 20/23 (87.0%) | 11/23 (47.8%) | 6/9 (66.7%) | 2/9 (22.2%) |
| MTX-based | 12/14 (85.7%) | 7/14 (50.0%) | 0/2 (0.0%) | 0/2 (0.0%) |
| CsA-based | 7/8 (87.5%) | 3/8 (37.5%) | 5/5 (100.0%) | 2/5 (40.0%) |
| CTX-based | 1/1 (100.0%) | 1/1 (100.0%) | 1/1 (100.0%) | 0/1 (0.0%) |
| Other therapies | 3/4 (75.0%) | 3/4 (75.0%) | ||
Abbreviations: CRR, complete response rates; Csa, cyclosporine; CTX, cyclophosphamide; MTX, methotrexate; ORR, overall response rates.
| Treatment . | The response rate to first-line therapy, n/N (%) . | The response rate to second-line therapy, n/N (%) . | ||
|---|---|---|---|---|
| ORR . | CRR . | ORR . | CRR . | |
| Immunosuppressor-based therapy | 20/23 (87.0%) | 11/23 (47.8%) | 6/9 (66.7%) | 2/9 (22.2%) |
| MTX-based | 12/14 (85.7%) | 7/14 (50.0%) | 0/2 (0.0%) | 0/2 (0.0%) |
| CsA-based | 7/8 (87.5%) | 3/8 (37.5%) | 5/5 (100.0%) | 2/5 (40.0%) |
| CTX-based | 1/1 (100.0%) | 1/1 (100.0%) | 1/1 (100.0%) | 0/1 (0.0%) |
| Other therapies | 3/4 (75.0%) | 3/4 (75.0%) | ||
| Treatment . | The response rate to first-line therapy, n/N (%) . | The response rate to second-line therapy, n/N (%) . | ||
|---|---|---|---|---|
| ORR . | CRR . | ORR . | CRR . | |
| Immunosuppressor-based therapy | 20/23 (87.0%) | 11/23 (47.8%) | 6/9 (66.7%) | 2/9 (22.2%) |
| MTX-based | 12/14 (85.7%) | 7/14 (50.0%) | 0/2 (0.0%) | 0/2 (0.0%) |
| CsA-based | 7/8 (87.5%) | 3/8 (37.5%) | 5/5 (100.0%) | 2/5 (40.0%) |
| CTX-based | 1/1 (100.0%) | 1/1 (100.0%) | 1/1 (100.0%) | 0/1 (0.0%) |
| Other therapies | 3/4 (75.0%) | 3/4 (75.0%) | ||
Abbreviations: CRR, complete response rates; Csa, cyclosporine; CTX, cyclophosphamide; MTX, methotrexate; ORR, overall response rates.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
